Poised for success with its breakthrough, handheld ultrasound solution for assessing and monitoring chronic liver disease, Sonic Incytes Medical Corp. has been named a top technology company in the 18th Annual “Ready to Rocket” list published by Rocket Builders today.
Ready to Rocket is a unique business recognition list that profiles technology companies with the greatest potential for growth. Each year, based on analysis of trends, Rocket Builders identifies the top private companies that are best positioned to capitalize on these trends to achieve growth. This selection methodology has been an accurate predictor of investment and business success with past “Ready to Rocket” companies.
“We identify companies that have both innovative technology and a fit within the industry value chain. Our analysis of the market and the company progress led to our selection of Sonic Incytes Medical Corp. as a Ready to Rocket Life Science company,” said Thealzel Lee, Senior Partner, Rocket Builders.
“We are honored to be recognized by Rocket Builders for our solution that has the potential to redefine the standard of care in quantifying fatty liver disease. Physicians will soon be able to accurately diagnose liver disease, which is a growing global health crisis, affecting 3 out of 10 people,” said George Aliphtiras, CEO, Sonic Incytes Medical Corp. “Access to a point of care diagnostic solution that replaces biopsy and MRI is an urgent unmet need for effective patient management. Our diagnostic solution, which is comparable to MRI, fits in the palm of a physician’s hand and is ideally positioned to address this emerging health crisis.”
Using technology similar to MRI elastography, Sonic Incytes’ ultrasound solution quantifies all liver disease using 3D liver tissue sampling. Combined with machine learning to enhance image guidance, it provides a confident assessment of liver health in all body types. Sonic Incytes plans to enter the market with its solution at the end of 2020.
About Sonic Incytes Medical Corp.
Sonic Incytes Medical Corp. has developed a breakthrough, handheld ultrasound solution for assessing and monitoring chronic liver disease. Sonic Incytes’ solution provides patients with a comfortable and non-invasive experience. Our procedure is easy enough to be performed by a medical assistant and produces immediate and reliable results at point of care. It can be adopted in any practice with minimal upfront investment and provides a potential new revenue stream for providers. Based in Vancouver, British Columbia, our medical device company is redefining the standard of care in quantifying fatty liver disease—with a diagnostic solution comparable to MRI—in the palm of your hand.
About the Rocket Recognition Program
The Rocket Recognition Program features two branded lists of companies. The “Ready to Rocket” list profiles information technology companies with the greatest potential for revenue growth in the coming year. The “Emerging Rockets” list profiles technology companies from multiple technology sectors with great potential for investment and market breakthroughs in the coming year. Both lists are predictive of future success making them unique in approach and unique in value for our business audience. “Ready to Rocket” and “Emerging Rockets” are trademarks of Rocket Builders, a respected management consulting firm servicing the technology industry.
For more information, please contact communications@www.sonicincytes.com.
